Cremieux on FDA Reform, Fake Data, and the Columbia Admissions Hack
About this episode
Drs. Anish Koka and Anthony DiGiorgio discuss FDA reform and research methodology with independent science writer Cremieux.
Episode Summary Drs. Anish Koka and Anthony DiGiorgio sit down with independent science writer Cremieux, the pseudonymous Substack author known for auditing primary data and calling out flawed research. The conversation ranges from FDA drug approval reform (Cremieux proposes a two-pathway system separating safety approval from insurer-facing efficacy approval), the divide between well-evidenced GLP-1s and unregulated peptides like BPC-157, and the HRT black-box warning controversy, to the Columbia and NYU admissions data leaks that made national news and implicated NYC mayor Zohran Mamdani. The back half digs into research methodology: why observational studies rarely replicate RCT findings, how Cremieux debunked a widely-cited Jonathan Haidt social media/cognition study, why the "administrator growth" chart doctors love to cite is likely exaggerated, and how publication bias correction methods work. Chapter Markers 00:00 Introduction and guest background 02:00 Why the pseudonym "Cremieux" 03:11 How he got into primary data analysis and writing 04:46 FDA drug approval reform — a two-pathway proposal 05:57 The peptide market: GLP-1s vs. unproven peptides like BPC-157 09:39 Should…
More episodes of The Doctor's Lounge
- Scott Becker on Building Becker's Healthcare, Physician Supply, and Private Enterprise
- Martin Shkreli on Drug Pricing, Prison, and the Fraud That Shook Pharma
- Do No Harm: Inside the Fight to Get Identity Politics Out of Medicine
- The Myocarditis Double Standard: COVID, the Vaccine, and the Pediatric Deaths That Went Unreported
- David Zweig on Schools, Science, and the Media's COVID Failure
- Drug Pricing, Broken Incentives, and the 340b program Fixes Washington Won't Touch
Explore listener stats, chart rankings, contacts and more on the The Doctor's Lounge podcast page.